Targeted health information misses the mark for Black Americans

Strategies used by doctors to increase patient engagement with health information may work with white Americans, but can backfire with Black Americans.

Amgen reports a 22% increase in Q1 2024 net revenues – Pharmaceutical Technology

Amgen has shelved obesity treatment AMG 786 and will continue forward with MariTide. Credits: Grand Warszawski /Shutterstock.com Amgen’s total revenues grew in Q1 2024 to

May 6, 2024

FDA Advisors’ Recommendation on Renal Denervation Hinges on Effectiveness Question

An FDA advisory committee will meet this week to discuss the durability and clinical effectiveness of renal denervation systems for the treatment of patients with

August 22, 2023

John Carroll on his cancer diagnosis; #ESMO’s biggest surprise; Lykos’ bad trip; Rate cuts, and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.